Immunocore Holdings plc financials

IMCR CIK 0001671927

Source: EDGAR filings · Built 2026-06-19T01:04:15Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -15.05M 20.89M -2.48M -51.41M -144.49M
EBITDA -42.25M -66.26M -55.55M -46.41M -166.99M
Working Capital 750.04M 717.68M 389.80M 373.14M
Net Debt -31.02M -23.01M -358.59M -321.02M
Gross Margin 98.73% 99.12% 99.58% 99.38% 100.00%
Operating Margin -11.34% -22.71% -23.91% -29.66% -4281.19%
Net Margin -8.88% -16.47% -22.17% -30.13% -4414.64%
Return on Equity (ROE) -9.32% -14.16% -14.99% -15.50% -77.03%
Return on Assets (ROA) -3.33% -5.06% -9.26% -9.97%
Current Ratio 4.04× 4.38× 3.80× 4.70×
Debt-to-Equity 1.15× 1.20× 0.23× 0.24×
Effective Tax Rate -85.94% 3.49% 9.20% -28.52% -0.08%
Cash Conversion Ratio 0.30× -0.51× -0.05× 0.94× 0.79×
Accruals Ratio -0.02× -0.08× -0.10× -0.01×
SBC % of Revenue 9.42% 11.02% 13.02% 18.86% 1198.97%
CapEx Coverage -2.47× 5.04× 0.54× -22.34× -103.25×
Free Cash Flow Per Share $-0.30 $0.42 $-0.05 $-1.12 $-3.40

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 400.02M 310.20M 249.43M 174.36M 4.08M
Revenues 249.43M 174.36M 36.48M
Cost of Revenue 5.09M 2.73M 1.04M 1.09M 0
Research and Development Expense 274.87M 222.15M 163.54M 101.92M 100.25M
Selling, General and Administrative Expense 165.41M 155.78M 144.50M 123.06M 110.82M
Operating Income (Loss) -45.35M -70.46M -59.65M -51.71M -174.59M
Income Tax Expense (Benefit) 16.41M -1.85M -5.60M 11.66M 150.00K
Net Income (Loss) Attributable to Parent -35.51M -51.09M -55.29M -52.54M -180.03M
Earnings Per Share, Basic $-0.71 $-1.02 $-1.13 $-1.15 $-4.24
Weighted Average Number of Shares Outstanding, Basic 50.35M 49.99M 48.89M 45.71M 42.49M
Earnings Per Share, Diluted $-0.71 $-1.02 $-1.13 $-1.15 $-4.24
Weighted Average Number of Shares Outstanding, Diluted 50.35M 49.99M 48.89M 45.71M 42.49M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 467.71M 455.73M 442.63M 402.47M
Assets, Current 996.74M 929.86M 528.82M 473.98M
Assets 1.07B 1.01B 597.00M 526.76M
Liabilities, Current 246.70M 212.18M 139.02M 100.83M
Liabilities 686.24M 648.79M 228.16M 187.86M
Stockholders' Equity Attributable to Parent 381.03M 360.72M 368.84M 338.90M 233.71M 76.91M
Common Stock, Shares, Outstanding 50.69M 50.06M 49.73M 48.09M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -10.71M 26.06M 2.94M -49.21M -143.11M
Payments to Acquire Property, Plant, and Equipment 4.34M 5.17M 5.42M 2.20M 1.39M
Net Cash Provided by (Used in) Investing Activities -16.34M -355.13M -5.42M -2.20M -1.28M
Net Cash Provided by (Used in) Financing Activities 12.37M 343.88M 34.35M 145.44M 288.19M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (IMCR CIK 0001671927), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

UEEC

UNITED HEALTH PRODUCTS, INC.

CXIIU

CHURCHILL CAPITAL CORP XII

MMTIF

MICROMEM TECHNOLOGIES INC.